SMT201500233B - Metodi per rilevare anticorpi anti-farmaco - Google Patents

Metodi per rilevare anticorpi anti-farmaco

Info

Publication number
SMT201500233B
SMT201500233B SM201500233T SM201500233T SMT201500233B SM T201500233 B SMT201500233 B SM T201500233B SM 201500233 T SM201500233 T SM 201500233T SM 201500233 T SM201500233 T SM 201500233T SM T201500233 B SMT201500233 B SM T201500233B
Authority
SM
San Marino
Prior art keywords
corps
methods
medicine anti
detect medicine
detect
Prior art date
Application number
SM201500233T
Other languages
English (en)
Inventor
Ermis Parussini
Guillaume Noguier
Original Assignee
Theradiag Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theradiag Sa filed Critical Theradiag Sa
Publication of SMT201500233B publication Critical patent/SMT201500233B/it

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/04—Investigating sedimentation of particle suspensions
    • G01N15/05—Investigating sedimentation of particle suspensions in blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SM201500233T 2010-04-29 2015-09-29 Metodi per rilevare anticorpi anti-farmaco SMT201500233B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32920110P 2010-04-29 2010-04-29
EP10305455 2010-04-29
EP11716417.8A EP2564202B1 (en) 2010-04-29 2011-04-28 Methods for detecting anti-drug antibodies
PCT/EP2011/056732 WO2011135024A1 (en) 2010-04-29 2011-04-28 Methods for detecting antibodies

Publications (1)

Publication Number Publication Date
SMT201500233B true SMT201500233B (it) 2016-01-08

Family

ID=42246049

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500233T SMT201500233B (it) 2010-04-29 2015-09-29 Metodi per rilevare anticorpi anti-farmaco

Country Status (19)

Country Link
US (2) US9063151B2 (it)
EP (1) EP2564202B1 (it)
JP (1) JP2013527444A (it)
KR (1) KR20130100908A (it)
CN (1) CN102884433A (it)
AU (1) AU2011247610A1 (it)
CA (1) CA2795549A1 (it)
CY (1) CY1116719T1 (it)
DK (1) DK2564202T3 (it)
ES (1) ES2548533T3 (it)
HR (1) HRP20151023T1 (it)
HU (1) HUE027662T2 (it)
IL (1) IL222533A0 (it)
PL (1) PL2564202T3 (it)
PT (1) PT2564202E (it)
RS (1) RS54249B1 (it)
SI (1) SI2564202T1 (it)
SM (1) SMT201500233B (it)
WO (1) WO2011135024A1 (it)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2564202T1 (sl) * 2010-04-29 2015-12-31 Theradiag Sa Metode za odkrivanje protiteles proti zdravilu
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
CN105765386B (zh) * 2013-10-31 2019-07-16 瑞泽恩制药公司 用于检测中和抗体的竞争性配体结合测定法
EP3084439B1 (en) * 2013-12-20 2018-09-19 Phadia AB Analysis of antibodies
US9304657B2 (en) 2013-12-31 2016-04-05 Abbyy Development Llc Audio tagging
WO2015166461A1 (en) * 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
EP2982987A1 (en) 2014-08-08 2016-02-10 Proteomika, S.L. Lateral flow immunoassays for the detection of antibodies against biological drugs
EP3215853B1 (en) * 2014-11-05 2022-11-16 F. Hoffmann-La Roche AG Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody
CN105277682A (zh) * 2015-11-17 2016-01-27 苏州浩欧博生物医药有限公司 一种抗TNF-α单抗药物抗体检测试剂盒
CN106093413A (zh) * 2016-07-18 2016-11-09 本·沙朗 一种抗英夫利西抗体elisa检测试剂盒和检测方法
KR20180052277A (ko) * 2016-11-10 2018-05-18 가톨릭대학교 산학협력단 항-제9응고인자 항체의 검출 방법 및 검출 키트
CN108535490A (zh) * 2017-03-06 2018-09-14 苏州和锐生物科技有限公司 生物制剂血药浓度检测方法及试剂
EP3652539A4 (en) * 2017-07-10 2021-03-31 Rambam Med-Tech Ltd. ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODIES IN ORGANIC MEDICINE TREATED PATIENTS AND USES THEREOF IN PERSONALIZED MEDICINE
JP2022540764A (ja) * 2019-06-25 2022-09-20 プロサイセデクス インコーポレイティド 抗ＴＮＦα生物製剤および抗薬剤抗体の検出
WO2023204378A1 (ko) * 2022-04-19 2023-10-26 의료법인 성광의료재단 혈액 내 항-약물항체 농도 측정을 통한 생물학적 약물에 대한 치료 반응성 예측 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520779A1 (en) 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. Agent for intra-airway administration
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
RU2370775C2 (ru) * 2003-07-29 2009-10-20 Дженентек, Инк. Анализ нейтрализующих антител и его применение
MX2008010920A (es) * 2006-03-09 2008-09-03 Hoffmann La Roche Prueba de anticuerpo anti-farmaco.
CN101506659B (zh) * 2006-09-12 2012-12-12 弗·哈夫曼-拉罗切有限公司 抗药物抗体测定法
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
MX2009012044A (es) 2007-05-07 2009-11-18 Wyeth Corp Eliminacion de interferencia en inmunoensayos causada por anticuerpos anti-carbohidrato.
WO2009077127A1 (en) * 2007-12-15 2009-06-25 F. Hoffmann-La Roche Ag Distinguishing assay
EP2240769A1 (en) 2008-01-15 2010-10-20 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
WO2009117791A2 (en) * 2008-03-28 2009-10-01 Katholieke Universiteit Leuven Mucosal gene signatures
EP2344884B1 (en) * 2008-10-07 2013-07-31 Gyros Patent Ab Semi-sequential assay for detection of an analyte in a sample
SI2564202T1 (sl) * 2010-04-29 2015-12-31 Theradiag Sa Metode za odkrivanje protiteles proti zdravilu

Also Published As

Publication number Publication date
HRP20151023T1 (hr) 2015-11-06
PL2564202T3 (pl) 2016-04-29
RS54249B1 (en) 2016-02-29
PT2564202E (pt) 2015-10-20
CY1116719T1 (el) 2017-03-15
US9063151B2 (en) 2015-06-23
WO2011135024A1 (en) 2011-11-03
EP2564202A1 (en) 2013-03-06
EP2564202B1 (en) 2015-07-01
US20130108631A1 (en) 2013-05-02
US9651560B2 (en) 2017-05-16
US20150285815A1 (en) 2015-10-08
CA2795549A1 (en) 2011-11-03
DK2564202T3 (en) 2015-10-05
IL222533A0 (en) 2012-12-31
ES2548533T3 (es) 2015-10-19
KR20130100908A (ko) 2013-09-12
AU2011247610A1 (en) 2012-12-13
CN102884433A (zh) 2013-01-16
SI2564202T1 (sl) 2015-12-31
JP2013527444A (ja) 2013-06-27
HUE027662T2 (en) 2016-10-28

Similar Documents

Publication Publication Date Title
SMT201500233B (it) Metodi per rilevare anticorpi anti-farmaco
DK2585140T3 (da) Autoinjektor
BR112013008072A2 (pt) autoinjetor
BR112013008401A2 (pt) autoinjetor
DK2536452T3 (da) Autoinjektor
DK2585137T3 (da) Autoinjektor
ES2638522T8 (es) Procedimientos para detectar cáncer
BR112014009799A2 (pt) imunoligantes dirigidos conra tnf
DK2654833T3 (da) Autoinjektor
BR112014007261A8 (pt) dispositivo de recolha de encomendas farmacêuticas
BR112013012217A2 (pt) incubadora
DK2654842T3 (da) Autoinjektor
DK2652652T3 (da) Medikmentadministration
BR112013007559A2 (pt) nutriente enteral
DK2575438T3 (da) Forbedret detekteringssystem
BR112013033747A2 (pt) sensores
BR112013008074A2 (pt) combinações farmacêuticas
FI20105335A0 (fi) Sydämen sykkeen havainnointi
BR112012022411A2 (pt) articulador
FIU20100025U0 (fi) Jalustarakenne
BR112014015885A8 (pt) preparação farmacêutica
DK2755701T3 (da) Injektorsamling
BR112013015785A2 (pt) autoinjetor
DK2590565T3 (da) Blodprøvetagning
BR112013000298A2 (pt) tablete